Pfizer expands into gene editing with Beam research deal

On Monday, Pfizer took a major step toward that vision, announcing a four-year research partnership with Beam Therapeutics, a high-profile biotech company that specializes in base editing and the mRNA components used to deliver such treatments into the body.